Treatment of mitral insufficency width a percutaneous approach (MITRACLIP)
- E-valve system: treatment of mitral insufficency width a percutaneous approach
- MitraClip: the percutaneous solution for mitral regurgitation
Although surgical therapy is the gold standard treatment for mitral regurgitation, in a number of cases the risk associated to the surgical operation is too high.
The low-risk solution is a percutaneous procedure using the MitraClip system.
The MitraClip is a device that reproduces the surgical Alfieri technique procedure: to correct the regurgitation, the leaflets are joined at the site of regurgitation using a clip, delivered by a sophisticated system, under 3D echocardiographic guidance.
The results of the EVEREST trial (Endovascular Valve Edge-to-Edge Repair Study), presented at the American College of Cardiology in March 2010, showed that the MitraClip therapy is safer than surgery and has similar efficacy in selected patients.
In Europe, the procedure is performed in selected centers, by specialized operators.
Our team has been involved in the very early stage of the development of the procedure and is now one of the leaders in Europe. The experience of the Milan Team working at San Raffaele Hospital and at Columbus Hospital is now over 50 patients treated with a 30 day mortality below 2%.
The procedure is performed with percutaneous transfemoral access in all patients, under general anesthesia to facilitate transesophageal echocardiography.
The MitraClip is mostly performed in individuals with “functional” mitral regurgitation, secondary to heart failure; however, also patients with prolapse can be treated efficiently. Depending on the underlying conditions, the hospital stay is as low as 3 days. Screening is based on transesophageal echo unless other exams are deemed necessary to complete the diagnosis.
In most cases, the patients are discharged within 2 days from the procedure.